Virtus ETF Advisers’s PDL BioPharma, Inc. PDLI Stock Holding History

Virtus ETF Advisers’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-198,901	Closed	-$666K	–	206
2016 Q3	$666K	Buy	198,901 +25,064	+14%	+$79.6K	0.32%	55
2016 Q2	$546K	Buy	173,837 +15,203	+10%	+$50.7K	0.41%	38
2016 Q1	$528K	Buy	+158,634	New	+$495K	0.73%	35

Other funds holding PDLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtus ETF Advisers's PDLI Position: Q4 2016 in Review

Virtus ETF Advisers sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 198,901 shares — an estimated $666K sold.

Virtus ETF Advisers first reported a position in PDLI in Q1 2016 and held it in 3 quarters. The position peaked at $666K in Q3 2016. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

Virtus ETF Advisers reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
Virtus ETF Advisers sold 198,901 PDL BioPharma, Inc. shares in Q4 2016, an estimated $666K.
Virtus ETF Advisers first reported a position in PDL BioPharma, Inc. in Q1 2016 and held it in 3 quarters.
Virtus ETF Advisers's PDL BioPharma, Inc. position peaked at $666K in Q3 2016.
190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.